CAR T-Cell Therapy vs Bispecific Antibodies for Patients With Refractory Multiple Myeloma
Naresh Bumma, MD, reviews how he selects between CAR T-cell therapy and bispecific agents for patients with refractory multiple myeloma.
EP: 1.Personalized Therapy Options Are on the Horizon in Multiple Myeloma
EP: 2.Treatment Approaches for Patients With Newly-Diagnosed Multiple Myeloma (NDMM)
EP: 3.Transplant Eligibility in Patients With NDMM
EP: 4.Treatment Considerations for Patients with High-Risk NDMM
EP: 5.First-Line Treatment Options for Patients With Transplant-Ineligible NDMM
EP: 6.Data Updates on the Treatment of Transplant-Ineligible NDMM From the MAIA Trial
EP: 7.Selecting Between Doublet and Triplet Regimens for Patients With Transplant-Ineligible NDMM
EP: 8.Available Treatment Options for Patients with Relapsed Multiple Myeloma
EP: 9.Updates on Bispecific T-Cell Engager (BiTE) Antibodies in Relapsed Multiple Myeloma
EP: 10.Other Bispecific Antibodies Under Investigation for Treatment of Relapsed Multiple Myeloma
Now Viewing
EP: 11.CAR T-Cell Therapy vs Bispecific Antibodies for Patients With Refractory Multiple Myeloma
EP: 12.Unmet Needs and Future Perspectives in Newly-Diagnosed and Relapsed Multiple Myeloma
Recent Videos
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
